Cytori Therapeutics (CYTX) Shares Gap Down to $0.33
Shares of Cytori Therapeutics Inc (NASDAQ:CYTX) gapped down prior to trading on Thursday . The stock had previously closed at $0.30, but opened at $0.33. Cytori Therapeutics shares last traded at $0.33, with a volume of 714541 shares changing hands.
CYTX has been the topic of several recent research reports. Maxim Group set a $5.00 price target on Cytori Therapeutics and gave the company a “buy” rating in a research note on Monday, November 13th. Zacks Investment Research downgraded Cytori Therapeutics from a “hold” rating to a “sell” rating in a research note on Thursday, November 9th. Finally, B. Riley reissued a “hold” rating on shares of Cytori Therapeutics in a research note on Tuesday, November 7th.
Cytori Therapeutics (NASDAQ:CYTX) last released its earnings results on Thursday, November 9th. The biotechnology company reported ($0.14) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.16) by $0.02. The business had revenue of $1.77 million for the quarter, compared to the consensus estimate of $2.04 million. Cytori Therapeutics had a negative return on equity of 228.21% and a negative net margin of 367.33%. During the same quarter in the previous year, the business earned ($0.26) earnings per share. sell-side analysts forecast that Cytori Therapeutics Inc will post -0.62 earnings per share for the current year.
A hedge fund recently raised its stake in Cytori Therapeutics stock. Sabby Management LLC lifted its stake in Cytori Therapeutics Inc (NASDAQ:CYTX) by 28.0% during the second quarter, according to the company in its most recent Form 13F filing with the SEC. The fund owned 1,626,807 shares of the biotechnology company’s stock after acquiring an additional 355,504 shares during the quarter. Sabby Management LLC owned approximately 4.69% of Cytori Therapeutics worth $1,789,000 as of its most recent SEC filing. Institutional investors own 7.41% of the company’s stock.
About Cytori Therapeutics
Cytori Therapeutics, Inc (Cytori) is a biotechnology company engaged in the development of treatments and devices for a range of disorders using cells as a key part of the therapy. The Company develops cellular therapeutics formulated and optimized for specific diseases and medical conditions and related products.
Receive News & Ratings for Cytori Therapeutics Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cytori Therapeutics Inc and related companies with MarketBeat.com's FREE daily email newsletter.